 Hepatitis B virus
"Hepatitis B virus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum.
| Descriptor ID |
D006515
|
| MeSH Number(s) |
B04.280.375.650.425 B04.450.390.650.425
|
| Concept/Terms |
Hepatitis B virus- Hepatitis B virus
- B virus, Hepatitis
- Hepatitis B viruses
- viruses, Hepatitis B
- Hepatitis Virus, Homologous Serum
|
Below are MeSH descriptors whose meaning is more general than "Hepatitis B virus".
Below are MeSH descriptors whose meaning is more specific than "Hepatitis B virus".
This graph shows the total number of publications written about "Hepatitis B virus" by people in this website by year, and whether "Hepatitis B virus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 2003 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 0 | 2 | 2 | | 2012 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 3 | 0 | 3 | | 2017 | 1 | 0 | 1 | | 2019 | 1 | 2 | 3 | | 2021 | 2 | 0 | 2 | | 2022 | 1 | 1 | 2 | | 2023 | 0 | 3 | 3 | | 2024 | 1 | 2 | 3 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Hepatitis B virus" by people in Profiles.
-
Martin GE, Hosking K, Banz K, Gargan C, Stewart G, Greenwood-Smith B, Ramsay P, Tate-Baker J, Connors C, Binks P, McKinnon M, Manchikanti P, Gurruwiwi GG, Allard N, Qama A, Michaels J, Vintour-Cesar E, Batey R, Marshall C, Nihill P, Fernandes TA, Fuller K, Tong SYC, Boettiger D, Cowie B, Davis JS, Bukulatjpi SM, Davies J. Disease progression & treatment need in sub-genotype C4 hepatitis B infection: a retrospective cohort study in the Northern Territory, Australia. BMC Infect Dis. 2025 Jul 01; 25(1):881.
-
Bokop C, Dhar N, Izu A, Thaver-Kleitman J, Prabdial-Sing N, Ali MM, Akaba G, Barsosio HC, Berkley JA, Beck MM, Chaka TE, Cutland CL, Dorji P, Islam M, Keita AM, Lema FB, Medugu N, Mwakio S, Obaro S, Olateju EK, Sahni RD, Saha SK, Santhanam S, Sharma R, Sigaúque B, Simoes EAF, Sow SO, Tapia MD, Veeraraghavan B, Kwatra G, Madhi SA. Prevalence of hepatitis B virus infection among pregnant women and cord blood hepatitis B surface antigen positive newborns in sub-Saharan Africa and South Asia. J Clin Virol. 2025 Aug; 179:105826.
-
Chiu CY, Sampathkumar P, Brumble LM, Vikram HR, Watt KD, Beam E. Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule. Vaccine. 2025 02 15; 47:126705.
-
Ryan P, Odegard E, Meeds H, Lartey M, Ganu VJ, Tachi K, Yang H, Ojewale O, Boamah I, Obo-Akwa A, Antwi K, Anderson PL, Blackard JT, Kwara A. Hepatitis B virus (HBV) viremia despite tenofovir disoproxil fumarate-containing antiretroviral therapy in persons with HBV/HIV coinfection. J Clin Virol. 2024 Dec; 175:105733.
-
Zhang HL, Mock M, Bushman L, Anderson PL, Kiser JJ, Naggie S. Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression. Clin Infect Dis. 2024 09 26; 79(3):705-708.
-
Bae J, Tantawy M, Gong Y, Langaee T, Lartey M, Ganu V, Tachi K, Ojewale O, Obo-Akwa A, Boamah I, Bushman LR, Ellison L, Yang H, Anderson PL, Kwara A. Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection. Antimicrob Agents Chemother. 2024 09 04; 68(9):e0054924.
-
Lartey M, Ganu VJ, Tachi K, Yang H, Anderson PL, Langaee T, Ojewale O, Boamah I, Obo-Akwa A, Antwi K, Bushman LR, Ellison L, Kwara A. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression. AIDS. 2024 03 01; 38(3):351-362.
-
Winkler F, Hipp AV, Ramirez C, Martin B, Villa M, Neuwirt E, Gorka O, Aerssens J, Johansson SE, Rana N, Llewellyn-Lacey S, Price DA, Panning M, Groß O, Pearce EL, Hermann CM, Schumann K, Hannibal L, Neumann-Haefelin C, Boettler T, Knolle P, Hofmann M, Wohlleber D, Thimme R, Bengsch B. Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+ T cells. Gut. 2023 10; 72(10):1971-1984.
-
Higgins DM, O'Leary ST. Prevention of Perinatal Hepatitis B Transmission. Obstet Gynecol Clin North Am. 2023 Jun; 50(2):349-361.
-
Thomas DL, Kiser JJ, Baum MM. Long-Acting Treatments for Hepatitis B. Clin Infect Dis. 2022 11 21; 75(Suppl 4):S517-S524.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|